Results 11 to 20 of about 2,840,126 (395)
Cancers, 2021 Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on
Cazzaniga M. E. +5 more
openaire +2 more sources
Systemic analysis of the AST results in medical organizations of the Russian Feder ation [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 Objective. To analyse aggregated AST results for key microorganisms collected through the 2022 reports of chief specialists in clinical microbiology and antimicrobial resistance. Materials and Methods.
Vinogradova A.G. +4 more
doaj +1 more source
Severe anaphylaxis caused by intravenous anti‐cancer drugs
Cancer Medicine, 2021 Background The incidence and risk factors of severe anaphylaxis by intravenous anti‐cancer drugs are unclear, whereas those of milder reactions have been reported.
Nobuyuki Horita +26 more
doaj +1 more source
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
New England Journal of Medicine, 2022 BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés +18 more
semanticscholar +1 more source
Antimicrobial resistance of clinical isolates of Klebsiella pneumoniae and Escherichia coli in Russian hospitals: results of a multicenter epidemiological study [PDF]
Клиническая микробиология и антимикробная химиотерапияObjective. To study the prevalence and mechanisms of antibiotic resistance, including carbapenemase production, in clinical isolates of Klebsiella pneumoniae and Escherichia coli isolated in different regions of Russia as part of the sentinel ...
Edelstein M.V. +12 more
doaj +1 more source
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi +28 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2021 PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab ...
M. Reck +18 more
semanticscholar +1 more source
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares +21 more
semanticscholar +1 more source
Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care [PDF]
, 2018 The role of induction chemotherapy in nasopharyngeal carcinoma (NPC) remains controversial. The primary aim of this study was to use the National Cancer Database to evaluate the patterns of care of induction chemotherapy in NPC and its impact on overall ...
Adkins, Douglas +10 more
core +2 more sources